Treatment of HBV recurrence after liver transplantation for HBV related liver diseases
10.3760/cma.j.issn.0254-1785.2015.04.005
- VernacularTitle:乙型肝炎相关性终末期肝病患者肝移植后乙型肝炎病毒感染复发的治疗
- Author:
Bacui ZHANG
;
Hong CHEN
;
Xu WANG
;
Tieyan FAN
;
Jun LI
;
Qing ZHANG
;
Xinguo CHEN
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Hepatitis B virus;
Recurrence;
Nucleoside analog;
Hepatitis B immunoglobulin
- From:
Chinese Journal of Organ Transplantation
2015;36(4):209-212
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the HBV recurrence and summarize the experiences in treatment of HBV recurrence after liver transplantation for HBV related liver diseases.Method A total of 650 patients subject to liver transplantation for HBV related liver diseases from September 2002 to February 2007 were included,and the clinical data were retrospectively analyzed.Result Twenty-five (3.85％) of 650 patients experienced HBV recurrence.All liver functions recovered to normal after nucleoside or nucleotide analogs treatment.Two cases lost to follow-up,2 cases were died of tumor recurrence,and 1 case died of tumor recurrence after re-transplantation.Eleven cases were positive for serum HBsAg,and HBV DNA was converted to undetectable levels in 10 cases.One case developed to decompensated liver cirrhosis,and HBsAg was negative after re-transplantation.In 7 cases,after nucleos(t)ide analogs treatment,HBsAg titer was decreased gradually to a lower level,and continuous intravenous drip of large doses of HBIG for 3 to 5 days achieved anti-HBs seroconversion.Conclusion Nucleos(t) ide analogs can effectively suppress viral replication of HBV recurrence after liver transplantation.When the HBsAg titer is decreased to a lower level,large doses of HBIG can achieve anti-HBs seroconversion.
